Updates are available Correction dated 2022-11-22

Article History

Received: 26 June 2022

Accepted: 14 October 2022

First Online: 1 November 2022

Change Date: 22 November 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00270-022-03318-5

Declarations

:

: Gustavo Oderich MD has received consulting fees and grants from Cook Medical, W. L. Gore, and GE Healthcare (all paid to Mayo Clinic with no personal income). Other co-authors declare that they have no conflict of interest.

: For this type of study, consent for publication is not required.

: Committee For the Protection of Human Subjects (CPHS) approved the study with all patients providing written informed consent.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This is a retrospective review of a prospective maintained database of patients treated by FB-EVAR conducted under the US Food and Drug Administration (FDA) PS-IDE G130030 and G130266 and registered under ClinicalTrial.gov NCT01937949 and NCT02089607. The study was approved by the Institutional Review Board at University of Texas Health Science Center at Houston and Mayo Clinic Rochester.

: Informed consent was obtained from all individual participants included in the study.